Value-based cancer care

New England Journal of Medicine

Volumn 373, Issue 27, 2015, Pages 2593-2595

  Young, Robert C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY; UNITED STATES; ECONOMICS; MEDICAL SOCIETY; NEOPLASMS;

DRUG COSTS; HEALTH CARE COSTS; HUMANS; NEOPLASMS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84952903757     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1508387     Document Type: Short Survey

References (5)

1. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015;33:2563-77.
2. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the Top Five list for oncology. J Clin Oncol 2012;30:1715-24.
3. Schnipper LE, Lyman GH, Blayney DW, et al. American Society of Clinical Oncology 2013 Top Five list in oncology. J Clin Oncol 2013;31:4362-70.
4. Levit L, Balogh E, Nass S, Ganz PA. Delivering high-quality cancer care: charting a new course for a system in crisis. Washington, DC: National Academies Press, 2013.
5. Porter ME, Lee TH. The strategy that will fix health care. Harvard Business Review. October 2013 (https://hbr.org/2013/10/the-strategy-that-will-fix-health-care).